ICCC
ImmuCell Corporation
10.00$
+0.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 49.5% | 53.9% | 58.1% | 21.9% | 19.6% | 34.1% | 30.1% | 36.6% | 31.2% | 26.2% | 33.4% | 39.8% | |
| 7.7% | 10.8% | 20.9% | 11.1% | 7.7% | 16.3% | 19.7% | 22.9% | 12.9% | 2.2% | 8.3% | 9.0% | |
| 30.2% | 41.3% | 43.0% | 11.1% | 7.7% | 22.7% | 19.7% | 22.9% | 12.9% | 2.2% | 8.3% | 9.0% | |
| 9.1% | 5.2% | 4.6% | 4.4% | 4.4% | 4.3% | 4.6% | 6.1% | 4.0% | 5.0% | 8.5% | 8.0% | |
| 8.6% | 6.0% | 8.6% | 6.0% | 7.1% | 6.5% | 5.2% | 6.9% | 13.5% | 17.8% | 15.8% | 21.8% | |
| 34.7% | 39.2% | 39.9% | 76.0% | 79.5% | 65.3% | 69.3% | 63.0% | 68,291.8% | – | – | – | |
| 0.0% | 0.0% | 0.4% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | |
| 0.0% | 0.0% | 0.7% | 0.4% | 0.4% | 0.3% | 0.2% | 0.2% | 0.1% | 0.1% | 0.0% | – | |
| 16.2% | 27.3% | 20.1% | 31.2% | 33.6% | 25.1% | 29.9% | 26.7% | 32.3% | 42.9% | 39.0% | 36.4% | |
| 9.1% | 5.6% | 8.3% | 6.0% | 7.8% | 6.4% | 5.5% | 5.7% | 6.8% | 9.6% | 9.8% | 9.4% | |
| 1.4% | 0.9% | 0.5% | 0.9% | 4.1% | 3.3% | 2.1% | 2.1% | 2.4% | 4.7% | 4.3% | 4.0% | |
| 4.1% | 1.4% | 6.1% | 3.6% | 1.8% | 1.5% | 1.5% | 1.7% | 1.8% | 2.0% | 2.1% | 1.9% | |
| 7.1% | 21.7% | 11.8% | 25.2% | 25.7% | 18.5% | 21.7% | 18.7% | 20.5% | 24.1% | 20.0% | 17.6% | |
| 83.8% | 72.7% | 79.9% | 68.8% | 66.4% | 74.9% | 70.1% | 73.3% | 67.7% | 57.1% | 61.0% | 63.6% | |
| -5.2% | 4.4% | 4.6% | 2.9% | -4.1% | -6.8% | -9.1% | -8.4% | -13.9% | -27.4% | -31.4% | -35.7% | |
| 27.4% | 21.7% | 17.6% | 14.4% | 16.8% | 17.6% | 17.9% | 17.1% | 17.3% | 17.7% | 18.1% | 21.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.